In 2023, Canada led the market in Global Modulators of the Genital System and Sex Hormones sales with $597.4 million PPP. Despite a 2.73% decline year-on-year, it remains a key player. Germany and Chile followed, with small increases of 1.27% and 4.24% respectively. In contrast, South Korea showed a significant growth of 6.63%. Conversely, countries like Finland and Slovenia saw declines of over 2%, with New Zealand showing a notable growth at 9.78%. The sales data reflect diverse market dynamics influenced by cultural, socioeconomic, and healthcare policy factors.
Future trends in this market to watch include potential growth in developing regions as healthcare access increases, advancements in biotechnology enhancing product effectiveness, and regulatory changes impacting market entry and competition. Additionally, demographic shifts, such as aging populations, could drive demand in specific markets.
Top countries in Modulators of the Genital System and Sex Hormones Sales by Country
| # | 10 Countries | Million US Dollars PPP | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Canada | 597.4 | 2023 | -1.69% | -2.73% | View data |
| 2 | 2 Germany | 543.9 | 2023 | +0.15% | +1.27% | View data |
| 3 | 3 Chile | 405.7 | 2023 | +9.21% | +4.24% | View data |
| 4 | 4 South Korea | 344.7 | 2023 | +3.86% | +6.63% | View data |
| 5 | 5 Australia | 230.7 | 2023 | +1.99% | +4.51% | View data |
| 6 | 6 Czech Republic | 174.5 | 2023 | +14.88% | +0.38% | View data |
| 7 | 7 Spain | 160.2 | 2023 | -16.17% | -0.84% | View data |
| 8 | 8 Croatia | 150.8 | 2023 | +0.94% | +0.7% | View data |
| 9 | 9 Sweden | 117 | 2023 | +0.34% | +2.4% | View data |
| 10 | 10 Portugal | 115.7 | 2023 | +1.49% | +1.67% | View data |
